Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of velusetrag in diabetic or idiopathic gastroparesis
2014-003250-13Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic gastroparesis and idiopathic gastroparesis (IG) comparing Velusetrag with Placebo (2 arms). Primary endpoint: Change in 7-day mean GCSI-DD composite score at Week 4 vs baseline and placebo. Started Mar 2015; status: completed.
02
Drugs
velusetrag
03
Conditions
diabetic gastroparesisidiopathic gastroparesis (IG)
Beyond the preview
Go deeper on 2014-003250-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003250-13.